spacer
home > epc > autumn 2003 > e-business in pharmacovigilance
PUBLICATIONS
European Pharmaceutical Contractor

e-Business in Pharmacovigilance

The greatest challenge of the 21st Century will be the introduction of integrated e-business processes into the daily routine of pharmacovigilance for all aspects of information creation, analysis and communication. The electronic communication is, however, only the externally visible part of information handling. The better the processes that precede or follow the communication are integrated and supported by intelligent data handling or production techniques, the higher the benefit from e-business.

In pharmacovigilance the task of collection, documentation distribution and regulatory reporting of case reports on adverse experiences related to drugs by pharmaceutical companies and regulatory authorities is predominant. Though this activity is only the first step in a decision-making process to determine the risk profile and ultimately the risk benefit ratio of a drug, it devours vast resources and is in the focus of most regulatory compliance measures. Individual case safety reports (ICSR) are exchanged through a tight and highly regulated network of mutual obligations. The same case safety report will therefore appear in multiple institutions and will be entered into a database.

Every day thousands of case safety reports (adverse event reports) are distributed throughout the world. The FDA alone received 276,000 case reports in 1999. There is reason to believe that this transaction is probably the most frequent communication in the pharmaceutical world. Until now, case safety reporting relied largely on paper-based formats, such as the CIOMS, MedWatch, Yellow Card, BfArM and others.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Peter-Christoph Schulz, Safety Officer at Bayer Vital GmbH

Dr Peter-Christoph Schulz is the Safety Officer at Bayer Vital GmbH, the German marketing organisation for the pharmaceutical products of Bayer AG. His current responsibilities include case handling and regulatory issue management, as well as IT development.

Dr Schulz's special interests include systems analysis, process engineering and application development for cardiology (EKG, Holter Monitoring), hospitals and pharmacovigilance. After the completion of medical school and service as a Medical Officer in the army, Dr Schulz trained in internal medicine in institutions in Germany and the US.

spacer
Dr Peter-Christoph Schulz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sustainability, plastics and Brexit: Keynote speakers set to inspire at PPMA Total Show 2019

Experts from IKEA, the British Plastics Federation and The Sunday Times to create a forum for education, knowledge-sharing and debate
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement